Invention Grant
- Patent Title: Combined therapy of alpha-1-antitrypsin and temporal T-cell depletion for preventing graft rejection
-
Application No.: US15477379Application Date: 2017-04-03
-
Publication No.: US10086070B2Publication Date: 2018-10-02
- Inventor: Eli Lewis
- Applicant: BEN GURION UNIVERSITY OF THE NEGEV RESEARCH AND DEVELOPMENT AUTHORITY
- Applicant Address: IL Beer Sheva
- Assignee: Ben Gurion University of the Neger Research and Development Authority
- Current Assignee: Ben Gurion University of the Neger Research and Development Authority
- Current Assignee Address: IL Beer Sheva
- Agency: Roach Brown McCarthy & Gruber, P.C.
- Agent Kevin D. McCarthy
- Main IPC: A61K38/57
- IPC: A61K38/57 ; A61K39/395 ; A61K35/39 ; A61K38/14 ; A61K38/19 ; A61K38/21 ; C07K16/40 ; A61K39/00
Abstract:
A method of preventing or treating xenotransplant rejection in a subject in need thereof is disclosed. The method comprises administering a therapeutically effective amount of alpha-1-antitrypsin (AAT) in combination with a therapeutically effective amount of an anti-CD8 antibody or an antigen binding fragment thereof.
Public/Granted literature
- US20170202961A1 COMBINED THERAPY OF ALPHA-1-ANTITRYPSIN AND TEMPORAL T-CELL DEPLETION FOR PREVENTING GRAFT REJECTION Public/Granted day:2017-07-20
Information query
IPC分类:
